Alunbrig (brigatinib)

pCPA File Number: 21467

Negotiation Status:

Concluded with an LOI

Indication(s):

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, previously untreated with an ALK inhibitor, in adult patients

Sponsor/Manufacturer:

Takeda Canada Inc.

CDA-AMC Project Number:

PC0230-000

pCPA Engagement Letter Issued:

2021-10-29

Negotiation Process Concluded:

2021-12-16